The National Institutes of Health (NIH) has announced a funding opportunity under the number RFA-CA-24-011, titled “Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed).” This grant, classified under the Cancer Detection and Diagnosis Research category (CFDA Number: 93.394), is designed to support the development and validation of emerging technologies that enhance the quality of samples used in cancer research. The grant offers an award ceiling of $300,000 and is part of the NIH’s commitment to advancing cancer research through innovative technologies.
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit grant applications for projects focused on further development and rigorous validation of new technologies that address pre-analytical degradation of targeted analytes in cancer-relevant biospecimens. The NOFO targets technologies where major feasibility gaps have been overcome, as evidenced by preliminary data, but still require further development and validation. The goal is to support the creation of innovative tools, devices, instrumentation, and methods that preserve sample integrity, establish verification criteria for quality assessment, and handle diverse conditions effectively. These technologies are expected to significantly accelerate and enhance research in cancer biology, early detection, clinical diagnosis, treatment, and epidemiology, as well as address issues related to cancer health disparities. By reducing pre-analytical variations affecting biospecimen sample quality, this funding opportunity aims to improve the reliability and impact of cancer research outcomes, ultimately leading to advancements in understanding and managing the disease.
Opportunity ID: 351176
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-24-011 |
| Funding Opportunity Title: | Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | |
| Expected Number of Awards: | |
| CFDA Number(s): | 93.394 — Cancer Detection and Diagnosis Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 28, 2023 |
| Last Updated Date: | Nov 28, 2023 |
| Original Closing Date for Applications: | Oct 01, 2024 |
| Current Closing Date for Applications: | Oct 01, 2024 |
| Archive Date: | Nov 06, 2024 |
| Estimated Total Program Funding: | |
| Award Ceiling: | $300,000 |
| Award Floor: | $ |
Eligibility
| Eligible Applicants: | Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Public housing authorities/Indian housing authorities State governments City or township governments Small businesses County governments Public and State controlled institutions of higher education For profit organizations other than small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Notice of Funding Opportunity (NOFO) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This NOFO will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-011.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact: NIH Grants Information
grantsinfo@nih.gov |